发明公开
EP3313852A1 SUBSTITUTED PYRAZOLO/IMIDAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS
审中-公开
作为PDE2抑制剂的取代吡唑并咪唑并双环化合物
- 专利标题： SUBSTITUTED PYRAZOLO/IMIDAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS
- 专利标题（中）： 作为PDE2抑制剂的取代吡唑并咪唑并双环化合物
-
申请号： EP16815100.9申请日： 2016-06-20
-
公开(公告)号： EP3313852A1公开(公告)日： 2018-05-02
- 发明人: MORRIELLO, Gregori J. , CHANG, Lehua , FORSTER, Ashley , CHEN, Yili , DWYER, Michael, P. , BERGER, Richard , WANG, Ming , NANDA, Kausik K. , BUNDA, Jaime L. , SHIPE, William D.
- 申请人： Merck Sharp & Dohme Corp.
- 申请人地址： 126 East Lincoln Avenue Rahway, NJ 07065-0907 US
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： 126 East Lincoln Avenue Rahway, NJ 07065-0907 US
- 代理机构： Jaap, David Robert
- 优先权： US201562184700P 20150625
- 国际公布： WO2016209749 20161229
- 主分类号： C07D498/04
- IPC分类号： C07D498/04 ; C07D491/04 ; C07D495/04
摘要：
The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
公开/授权文献
信息查询
